Production of large quantities of 90Y by ion-exchange chromatography using an organic resin and a chelating agent

Nuclear Medicine and Biology

Volumn 37, Issue 8, 2010, Pages 935-942

  Castillo, Abmel Xiques ^a   Pérez Malo, Marylaine ^a   Isaac Olivé, Keila ^a   Mukhallalati, Heyam ^b   González, Edgar Casanova ^a   Berdeguez, Mirta Torres ^a   Díaz, Néstor Cornejo ^c  

^a Centro de Isotopos Cuba   (Cuba)

^b DEPARTMENT OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Syrian Arab Republic)

^c Centro de Proteccion e Higiene de las Radiaciones   (Cuba)

Author keywords

90Sr 90Y generator; 90Y for targeted therapy; 90Y production; Ion exchange separation

Indexed keywords

CATION EXCHANGE RESIN; DOWEX 50WX8; EDETIC ACID; STRONTIUM 90; UNCLASSIFIED DRUG; YTTRIUM 90;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COST; DRUG ISOLATION; DRUG PURIFICATION; FLOW RATE; PH; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RADIOCHEMISTRY; REACTION TIME;

CHELATING AGENTS; CHROMATOGRAPHY, ION EXCHANGE; EDETIC ACID; ION EXCHANGE RESINS; STRONTIUM RADIOISOTOPES; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 78049461365     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.03.017     Document Type: Article

References (37)

1. 90Y] colloid in rheumatoid arthritis and related indications. Rheumatology (Oxford) 2007, 46:16.
2. Gulec S.A., Mesoloras G., Dezarn W.A., McNeillie P., Kennedy A.S. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of the tumor to liver flow ratio. J Transl Med 2007, 5:15.
3. Paganelli G., Bartolomei M., Grana C., Ferrari M., Rocca P., Chinol M. Radioimmunotherapy of brain tumour. Neurol Res 2006, 28:518.
4. Witzig T.E., Molina A., Gordon L.I., Emmanouilides C., Schilder R.J., Flinn I.W., et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007, 109:1804.
5. Davies A.J. Radioimmunotherapy for B-cell lymphoma: Y-90 ibritumomab tiuxetan and I-131 tositumomab. Oncogene 2007, 26:3614.
6. Grillo-Lopez A.J. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002, 2:485.
7. 90Sr. U.S. Patent Application 20030231994 2003.
8. 90Y generator using zirconium antimonate. Appl Radiat Isot 1993, 45:415.
9. Chinol M., Hnatowich D.J. Generator produced yttrium-90 for radioimmunotherapy. J Nucl Med 1987, 28:1465.
10. 90Y radioisotope generator. Int J Appl Radiat Isot 1978, 29:91.
11. Chinol M., Francceschini R., Paganelli G. Process for producing yttrium-90-labelled protein substrate. U.S. Patent 5902566 1999.
12. 90Sr. J Nucl Med 1963, 4:54.
13. 90Sr with ion-exchange. Int J Appl Radiat Isot 1964, 15:599.
14. 90Y generator for medical purpose. J Radioanal Nucl Chem 2000, 245:403.
15. 90Sr. Int J Appl Radiat Isot 1970, 22:567.
16. Wike J.S., Guyer C.E., Ramey D.W., Phillips B.P. Chemistry for commercial scale production of yttrium-90 for medical research. Appl Radiat Isot 1990, 41:861.
17. 90Y on specially developed centrifugal semicounterflow extractors. Radiochemistry 2002, 44:61.
18. 90Y suitable for targeted therapy. Nucl Med Biol 2008, 35:245.
19. 90Y, a therapeutic medical radioisotope. Appl Radiat Isot 2003, 59:35.
20. Bray L.A. Method for separating and purifying Yttrium-90 from Strontium-90. WO 2006/025975 2006, World Intellectual Property Organization.
21. Dietz L.M., Horwitz E.P. Improved chemistry for production of yttrium-90 for medical applications. Appl Radiat Isot 1992, 43:1093.
22. Boll R.A., Malkemus D., Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiat Isot 2005, 62:667.
23. L'Annunziata M.F. Liquid scintillation analysis: principles and practice. Multiple radionuclide analysis. Handbook of radioactivity analysis 2003, 418. Academic Press, London, Great Britain. 2nd ed.
24. L'Annunziata M.F. Liquid scintillation analysis: principles and practice. Radionuclide standardization. Handbook of radioactivity analysis 2003, 445. Academic Press, London, Great Britain. 2nd ed.
25. Nowack B., Kari F.G., Hilger S.U., Sigg L. Determination of dissolved and adsorbed EDTA species in water and sediments by HPLC. Anal Chem 1996, 68:561.
26. 90Y for clinical use. Radiochim Acta 2009, 97:739.
27. Cross W.G., Freedman N.O., Wong P.Y. Table of beta-ray dose distribution in water. Atomic Energy of Canada AECL-Report 10521 1992.
28. Briesmeister J.F. MCNP - a general Monte Carlo N-particle transport code, version 4C. CCC-700 2000, Los Alamos National Laboratory, Los Alamos, New Mexico.
29. Simpkin D.J., Mackie T.R. EGS4 Monte Carlo determination of the beta dose kernel in water. Med Phys 1990, 17:179.
30. Bhattacharyya S.N., Kurdu K.P. X-Irradiation of aqueous solutions of ethylenediaminetetraacetic acid (EDTA). J Radioanal Nucl Chem 1972, 4:31.
31. Höbel B., Sonntag C. OH-Radical induced degradation of ethylenediaminetetraacetic acid (EDTA) in aqueous solution: a pulse radiolysis study. J Chem Soc Perkin Trans 1998, 2:509.
32. Toste A.P. Gamma radiolysis of EDTA in a simulated, mixed nuclear waste. J Radioanal Nucl Chem 1998, 235:213.
33. USP monographs: yttrium Y-90 ibritumomab tiuxetan injection. http://www.pharmacopeia.cn/v29240/usp29nf24s0_m89430.html.
34. Pillay K.K.S. A review of the radiation stability of ion exchange materials. J Radioanal Nucl Chem 1986, 102:247.
35. Van Loon LR, Hummel W. The radiolytic and chemical degradation of organic ion exchange resins under alkaline conditions. Paul Scherrer Institute, Technical Report. Würenlingen and Villigen 1995, p.6.
36. Frizon F., Cau-dit-Coumes C. Cementation of ILW ion exchange resins: impact of sulfate ions released by radiolysis on hydrated matrix. J Nucl Mat 2006, 359:162.
37. Marhol M. Ion exchangers in analytical chemistry 1982, 25. Academia Praga, Prague.